Related references
Note: Only part of the references are listed.Meta-Analysis of Hepatic Cytochrome P450 Ontogeny to Underwrite the Prediction of Pediatric Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling
Vijay V. Upreti et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents
Michael Neely et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Saturated Metabolism of Voriconazole N-Oxidation Resulting in Non linearity of Pharmacokinetics of Voriconazole at Clinical Doses
Takahiro Yamada et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review
Hazem Elewa et al.
CLINICAL PHARMACOKINETICS (2015)
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
Hyewon Chung et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Population Pharmacokinetic Analysis of Voriconazole and Anidulafungin in Adult Patients with Invasive Aspergillosis
Ping Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Up to date epidemiology, diagnosis and management of invasive fungal infections
I. Oren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
Taotao Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
Taotao Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
Michael J. Dolton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Neonatal clinical pharmacology
Karel Allegaert et al.
PEDIATRIC ANESTHESIA (2014)
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes
J. Kevin Hicks et al.
PHARMACOGENOMICS (2014)
Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients
Imke H. Bartelink et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
A Bayesian Dose-Individualization Method for Warfarin
Daniel F. B. Wright et al.
CLINICAL PHARMACOKINETICS (2013)
Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children
R. N. Hines
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Determination of Voriconazole in Human Plasma by HPLC-ESI-MS and Application to Pharmacokinetic Study
Dai Lin et al.
JOURNAL OF CHROMATOGRAPHIC SCIENCE (2013)
Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children
Atsushi Narita et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
Importance of Voriconazole Therapeutic Drug Monitoring in Pediatric Cancer Patients With Invasive Aspergillosis
Soo-Han Choi et al.
PEDIATRIC BLOOD & CANCER (2013)
Population Pharmacokinetics of Voriconazole in Adults
William W. Hope
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults
Lena E. Friberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Wan Beom Park et al.
CLINICAL INFECTIOUS DISEASES (2012)
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
SeungHwan Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Therapeutic Drug Monitoring of Voriconazole in Children
Jennifer Chen et al.
THERAPEUTIC DRUG MONITORING (2012)
Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults
Timothy A. Driscoll et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Voriconazole plasma levels in children are highly variable
I. Spriet et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2011)
Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation
Daniel F. B. Wright et al.
PHARMACEUTICAL RESEARCH (2011)
Evaluating Performance of a Decision Support System to Improve Methotrexate Pharmacotherapy in Children and Young Adults With Cancer
Erin Dombrowsky et al.
THERAPEUTIC DRUG MONITORING (2011)
Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
Claudia Michael et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children
Thomas J. Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Oral Voriconazole Dose in Children: One Size Does Not Fit All
Sylvain Goutelle et al.
CLINICAL INFECTIOUS DISEASES (2010)
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Michael Neely et al.
CLINICAL INFECTIOUS DISEASES (2010)
Epidemiology of invasive fungal infections in neonates and children
W. J. Steinbach
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Voriconazole concentrations and outcome of invasive fungal infections
S. Miyakis et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
Hui-Yan Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
Mats O. Karlsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
Roger J. M. Bruggemann et al.
CLINICAL INFECTIOUS DISEASES (2009)
Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues
M. C. Arendrup et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Invasive candidiasis in pediatric intensive care units
Sunit Singhi et al.
INDIAN JOURNAL OF PEDIATRICS (2009)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
Koki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population Pharmacokinetics of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Recipients: New Initial Dosage Suggestions and a Model-Based Dosage Adjustment Tool
Johan E. Wallin et al.
THERAPEUTIC DRUG MONITORING (2009)
Overview of Therapeutic Drug Monitoring
Ju-Seop Kang et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2009)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals
Yasmine Nivoix et al.
CLINICAL PHARMACOKINETICS (2008)
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
Anshul Gupta et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Mark-David Levin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)
Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight
K. Frankenbusch et al.
JOURNAL OF PERINATOLOGY (2006)
Clinical pharmacokinetics of voriconazole
Dominique Levque et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
K Tan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2006)
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics
J Rengelshausen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Antifungal agents in children
WJ Steinbach
PEDIATRIC CLINICS OF NORTH AMERICA (2005)
Successful treatment of cerebral blastomycosis with voriconazole
M Bakleh et al.
CLINICAL INFECTIOUS DISEASES (2005)
Developmental expression of human hepatic CYP2C9 and CYP2C19
SB Koukouritaki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants
D Kaufman et al.
CLINICAL MICROBIOLOGY REVIEWS (2004)
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans
SM Hariprasad et al.
ARCHIVES OF OPHTHALMOLOGY (2004)
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration
TJ Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
Y Ikeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
SJ Roffey et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Voriconazole does not affect the steady-state pharmacokinetics of digoxin
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
L Purkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
TJ Walsh et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
M Sandström et al.
BONE MARROW TRANSPLANTATION (2001)
Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole
A Reis et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2000)
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma
S Perea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
